Group 1 - The company, Wanfu Biology, announced that its fifth board meeting will be held on October 21, 2025, via communication methods [1] - The meeting will review the proposal regarding not adjusting the conversion price of the convertible bonds [1] Group 2 - The interview with He Keng emphasizes the need to shift funding focus from excessive concentration on housing and infrastructure to enhancing investments in the livelihood sector [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-060 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"本公司"）第五届 董事会第十五次会议于 2025 年 10 月 21 日下午 15:00 在公司会议室以通讯方式 召开，会议通知于 2025 年 10 月 21 日以邮件、电话的方式向全体董事发出。会 议应到董事 7 名，实到 7 名，出席会议人数符合《公司法》和《公司章程》规 定。会议由公司董事长王继华女士主持。 经与会董事认真审议，本次会议通过以下议案： 一、审议通过《关于不向下修正可转换公司债券转股价格的议案》 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券 募集说明书》（以下简称"募集说明书"）中相关条款，截至 2025 年 10 月 21 日， 公司股票在任意连续三十个交易日中至少有十五个 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 10 月 21 日，广州万孚生物技术股份有限公司（以下简称 "公司"）股票已触发"万孚转债"转股价格向下修正条款。 2、公司于 2025 年 10 月 21 日召开第五届董事会第十五次会议，审议通过 了《关于不向下修正可转换公司债券转股价格的议案》，公司董事会决定本次 不向下修正"万孚转债"转股价格，且自董事会审议通过次一交易日起未来三 个月内（即 2025 年 10 月 22 日至 2026 年 1 月 21 日），如再次触发"万孚转债" 转股价格向下修正条款，亦不提出向下修正方案。自 2026 年 1 月 22 日起算， 若再次触发"万孚转债"转股价格的向下修正条款，届时公司董事会将再次召 开会议决定是否行使"万孚转债"转股价格的向下修正权利。 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-061 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于不向下修正 ...

Core Viewpoint - The company announced that its stock price has been below 80% of the current conversion price for 10 trading days, which may trigger a downward adjustment of the conversion price for its convertible bonds [1] Group 1 - The stock price of Guangzhou Wanfu Biological Technology Co., Ltd. has been below the conversion price of 21.60 yuan per share since September 19, 2025 [1] - The company will hold a board meeting to decide whether to adjust the conversion price if the conditions for adjustment are triggered [1] - The company commits to timely information disclosure following the board's decision [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 转股价格：人民币 27.00 元/股 转股时间：2021 年 3 月 8 日至 2026 年 8 月 31 日 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）中相关约定：在本次发行的可转换公司 债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的 80%时，公司董事会有权提出转股价格向下修正方案并 提交公司股东大会表决。上述方案须经出席会议的股东所持表决权的三分之二以 上通过方可实施。 广州万孚生物技术股份有限公司（以下简称"公司"）股票自 20 ...

Core Points - Wanfu Biological announced a stock repurchase plan, with a total of 13,000 shares repurchased, representing 0.0028% of the company's total share capital [2] Summary by Category Company Actions - The company has implemented a stock repurchase through a dedicated account, utilizing centralized bidding transactions [2] - The repurchase is set to continue until September 30, 2025 [2] Financial Impact - The total number of shares repurchased is 13,000, which is a small fraction of the overall share capital [2] - The repurchase represents 0.0028% of the company's total equity [2]

Core Viewpoint - Wanfu Biological (300482.SZ) has conducted a share buyback, acquiring a total of 13,000 shares, which represents 0.0028% of the company's total share capital, in compliance with its buyback plan and relevant regulations [1] Summary by Categories - **Share Buyback Details** - The company implemented the buyback through a special account for stock repurchase via centralized bidding [1] - The highest transaction price for the repurchased shares was 21.21 yuan per share, with the lowest also being 21.21 yuan per share [1] - The total amount spent on the buyback was 275,729.00 yuan, excluding transaction fees [1]

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在回购期间每个月的前三个交易日内 披露截至上月末的回购进展情况，现将具体情况公告如下： 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开的第五届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式回购公司已发行的人民币普通股股 份，用于员工持股计划和股权激励。本次用于回购股份的资金总额不低于人民币 3,000 万元且不超过人民币 6,000 万元（均包含本数），回购价格不超过人民币 34.66 元/股（含），回购实施期限自公司董事会审议通过本次回购方案之日起 6 个月内。具体内容详见公司刊登在中国证监会指定创业板信息披露网站上的相关 公告。 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、回购公司股份的进展情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前三个交 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：300482 | | 证券简称：万孚生物 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：123064 | | 债券简称：万孚转债 | | | | | | | | 转股价格：人民币 | | 27.00 元/股 | | | | | | | | 转股时间：2021 | 年 3 | 月 8 | 日至 | 2026 | 年 | 8 月 | 31 | 日 | 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所可转换公司 债券业务实施细则》的有关规定，广州万孚生物技术股份有限公司（以下简称"公 司"）现将 2025 年第三季度可转换公司债券（以下简称"可转债"）转股及公司股 份变动的情况公告如下： 一、 ...

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 29 yuan [2][8]. Core Views - The company's performance is under pressure in the short term, with a significant decline in revenue and profit. The total revenue for the first half of 2025 was 1.246 billion yuan, down 20.92%, and the net profit attributable to shareholders was 189 million yuan, down 46.82% [2][3]. - The company is making steady progress in expanding its overseas business, which is expected to help mitigate domestic market challenges [2][8]. Financial Summary - **Revenue and Profit Forecasts**: The projected total revenue for 2025 is 2.634 billion yuan, reflecting a year-on-year decrease of 14.1%. The net profit attributable to shareholders is expected to be 418 million yuan, down 25.5% [4][9]. - **Earnings Per Share (EPS)**: The EPS for 2025 is forecasted at 0.89 yuan, with a price-to-earnings (P/E) ratio of 24 [4][9]. - **Market Capitalization**: The total market capitalization of the company is approximately 9.956 billion yuan [5]. Business Segment Performance - **Chronic Disease Management Testing**: Revenue for this segment was 563 million yuan, down 26.06%. The company is responding to domestic market pressures by launching new products and enhancing its service model [8]. - **Infectious Disease Testing**: Revenue decreased to 379 million yuan, down 21.14%. The company is focusing on maintaining its market position while expanding its product offerings in overseas markets [8]. - **Drug Abuse Testing**: This segment showed a stable growth with revenue of 145 million yuan, up 4.26%, driven by e-commerce strategies [8]. - **Prenatal and Genetic Testing**: Revenue was 138 million yuan, down 11.67%, as the company focuses on product innovation to adapt to market changes [8]. Investment Recommendations - The report suggests that considering the domestic demand for products, the pace of international expansion, and stock compensation expenses, the net profit attributable to shareholders is expected to be 4.2 billion yuan, 4.9 billion yuan, and 5.9 billion yuan for 2025, 2026, and 2027 respectively [8].